MX2010005893A - Marcadores de expresion genica para enfermedad inflamatoria de intestino. - Google Patents
Marcadores de expresion genica para enfermedad inflamatoria de intestino.Info
- Publication number
- MX2010005893A MX2010005893A MX2010005893A MX2010005893A MX2010005893A MX 2010005893 A MX2010005893 A MX 2010005893A MX 2010005893 A MX2010005893 A MX 2010005893A MX 2010005893 A MX2010005893 A MX 2010005893A MX 2010005893 A MX2010005893 A MX 2010005893A
- Authority
- MX
- Mexico
- Prior art keywords
- inflammatory bowel
- bowel disease
- gene expression
- expression markers
- test sample
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99120307P | 2007-11-29 | 2007-11-29 | |
| PCT/US2008/064562 WO2008147900A2 (en) | 2007-05-22 | 2008-05-22 | Gene expression markers for inflammatory bowel disease |
| US19226808P | 2008-09-17 | 2008-09-17 | |
| PCT/US2008/085045 WO2009073565A2 (en) | 2007-11-29 | 2008-11-26 | Gene expression markers for inflammatory bowel disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010005893A true MX2010005893A (es) | 2011-03-04 |
Family
ID=40459795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010005893A MX2010005893A (es) | 2007-11-29 | 2008-11-26 | Marcadores de expresion genica para enfermedad inflamatoria de intestino. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2261367A3 (enExample) |
| JP (1) | JP2011509071A (enExample) |
| KR (1) | KR20110015409A (enExample) |
| CN (1) | CN101970689A (enExample) |
| AU (1) | AU2008334095A1 (enExample) |
| CA (1) | CA2706729A1 (enExample) |
| IL (2) | IL206014A (enExample) |
| MX (1) | MX2010005893A (enExample) |
| WO (1) | WO2009073565A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010276392A1 (en) * | 2009-07-20 | 2012-03-08 | Genentech, Inc. | Gene expression markers for Crohn's disease |
| EP2486130A1 (en) * | 2009-10-06 | 2012-08-15 | Tallinn University Of Technology | Inhibition or activation of serine/threonine ulk3 kinase activity |
| WO2011127351A1 (en) * | 2010-04-09 | 2011-10-13 | Exagen Diagnostics, Inc. | Biomarkers for ulcerative colitis and crohn's disease |
| EP2576838A4 (en) * | 2010-06-04 | 2019-05-15 | Nestec S.A. | METHOD FOR IMPROVING DIAGNOSIS OF INFLAMMATORY ENDURANCE |
| KR101394197B1 (ko) * | 2012-08-17 | 2014-05-30 | 관동대학교산학협력단 | 염증성 장 질환과 연관된 단일염기다형성 정보를 제공하는 방법 |
| WO2014139182A1 (en) | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| CN103336914B (zh) * | 2013-05-31 | 2016-05-25 | 中国人民解放军国防科学技术大学 | 一种提取荟萃生物标志物的方法及装置 |
| EP3736340A1 (en) * | 2014-08-28 | 2020-11-11 | The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth | Methods and kit for identification of cancer |
| JP6192177B2 (ja) * | 2015-05-25 | 2017-09-06 | ヤマサ醤油株式会社 | 炎症性腸疾患のバイオマーカーとしてのｓ１００ａ９の使用 |
| JP7082945B2 (ja) * | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
| GB201611738D0 (en) * | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
| CA3056911A1 (en) * | 2017-03-23 | 2018-09-27 | Meharry Medical College | Methods for diagnosing and treating inflammatory bowel disease |
| CA3067397A1 (en) * | 2017-06-20 | 2018-12-27 | Meharry Medical College | Targeted defa5 antibody and assay methods for diagnosing and treating inflammatory bowel disease |
| EP3774848B1 (en) * | 2018-03-29 | 2023-02-22 | Lateral Ip Pty Ltd | Cyclic peptides and uses thereof |
| CN110577953B (zh) * | 2018-06-11 | 2024-02-20 | 深圳华大生命科学研究院 | 基因突变体及其应用 |
| CN108893488A (zh) * | 2018-06-19 | 2018-11-27 | 刘志强 | 一种重组质粒、dna疫苗及其制备方法和应用 |
| WO2020000436A1 (zh) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | 一种特异靶向人INDO基因的gRNA导向序列及其应用 |
| EP3821246A4 (en) * | 2018-07-15 | 2022-06-22 | Rambam Med-Tech Ltd. | Determining responders to inflammation treatment |
| CN110241116B (zh) * | 2019-05-21 | 2023-02-07 | 中国医学科学院放射医学研究所 | 一种环状rna及在促进dna损伤修复中的应用 |
| US12293809B2 (en) | 2019-08-23 | 2025-05-06 | Insilico Medicine Ip Limited | Workflow for generating compounds with biological activity against a specific biological target |
| JP2021185817A (ja) * | 2020-05-29 | 2021-12-13 | 独立行政法人国立病院機構 | バイオマーカー及びインターフェロンγ関連遺伝子のバイオマーカーとしての使用 |
| WO2025029562A1 (en) * | 2023-07-28 | 2025-02-06 | The Johns Hopkins University | Dna vaccines for eliciting t cell immunity in the lung |
| CN119236059B (zh) * | 2024-10-11 | 2025-04-18 | 广东医科大学附属医院 | Pdlim4基因在制备抑制非小细胞肺癌增殖的药物中的应用 |
| CN119798401B (zh) * | 2024-12-30 | 2025-10-10 | 常州因普迈生物科技有限公司 | 基于pdzk1ip1蛋白的多肽、抗体及其应用 |
| CN120510912A (zh) * | 2025-05-20 | 2025-08-19 | 北京大学人民医院 | 用于溃疡性结肠炎预测计算机装置及计算机可读存储介质 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| DK0527283T3 (da) | 1991-08-12 | 1998-08-10 | Nestle Sa | Levnedsmiddelsammensætning |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| EP0626012B1 (en) | 1992-02-11 | 2003-07-09 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| US6283761B1 (en) | 1992-09-08 | 2001-09-04 | Raymond Anthony Joao | Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information |
| US20030198640A1 (en) * | 1994-11-07 | 2003-10-23 | Human Genome Sciences, Inc. | Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2223198A1 (en) | 1997-01-14 | 1998-07-14 | Societe Des Produits Nestle S.A. | Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
| US20010010924A1 (en) * | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| MXPA01008936A (es) * | 1999-03-04 | 2003-07-21 | Human Genome Sciences Inc | Receptores 6 alfa y 6 beta del factor de necrosis tumoral. |
| EP1287162A2 (en) * | 1999-10-21 | 2003-03-05 | Case Western Reserve University | Gene expression profiling of inflammatory bowel disease |
| DK1272647T3 (en) | 2000-04-11 | 2014-12-15 | Genentech Inc | Multivalent antibodies and uses thereof |
| GB0130955D0 (en) | 2001-12-24 | 2002-02-13 | Cancer Res Ventures | Expression system |
| WO2003064621A2 (en) | 2002-02-01 | 2003-08-07 | Ambion, Inc. | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| EP1644858B1 (en) | 2003-07-10 | 2017-12-06 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| EP1844158A4 (en) * | 2004-12-06 | 2010-09-08 | Univ Johns Hopkins | BIOMARKER FOR INFLAMMATORY ENDURANCE |
| WO2007081486A2 (en) * | 2005-12-15 | 2007-07-19 | Ventria Bioscience | Oral administration of defensins to treat intestinal diseases |
| AU2009215441B2 (en) * | 2008-02-19 | 2015-07-02 | The Children's Hospital Of Philadelphia | Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same |
-
2008
- 2008-11-26 MX MX2010005893A patent/MX2010005893A/es not_active Application Discontinuation
- 2008-11-26 CN CN2008801258460A patent/CN101970689A/zh active Pending
- 2008-11-26 CA CA2706729A patent/CA2706729A1/en not_active Abandoned
- 2008-11-26 JP JP2010536200A patent/JP2011509071A/ja active Pending
- 2008-11-26 EP EP10008262A patent/EP2261367A3/en not_active Withdrawn
- 2008-11-26 AU AU2008334095A patent/AU2008334095A1/en not_active Abandoned
- 2008-11-26 KR KR1020107014096A patent/KR20110015409A/ko not_active Ceased
- 2008-11-26 WO PCT/US2008/085045 patent/WO2009073565A2/en not_active Ceased
-
2010
- 2010-05-27 IL IL206014A patent/IL206014A/en not_active IP Right Cessation
-
2014
- 2014-06-29 IL IL233432A patent/IL233432A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101970689A (zh) | 2011-02-09 |
| AU2008334095A1 (en) | 2009-06-11 |
| JP2011509071A (ja) | 2011-03-24 |
| AU2008334095A2 (en) | 2010-07-15 |
| KR20110015409A (ko) | 2011-02-15 |
| EP2261367A2 (en) | 2010-12-15 |
| EP2261367A3 (en) | 2011-03-23 |
| IL206014A (en) | 2014-07-31 |
| IL233432A0 (en) | 2014-08-31 |
| IL206014A0 (en) | 2010-11-30 |
| WO2009073565A2 (en) | 2009-06-11 |
| WO2009073565A3 (en) | 2009-09-24 |
| CA2706729A1 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010005893A (es) | Marcadores de expresion genica para enfermedad inflamatoria de intestino. | |
| EP2757160A3 (en) | Gene expression markers for Crohn's disease | |
| MX2009008736A (es) | Metodos para detectar la enfermedad inflamatoria intestinal. | |
| EP2021794B8 (en) | Use of protein s100a 12 as a marker for colorectal cancer | |
| EA201600085A1 (ru) | Набор для обнаружения соевого события syht0h2 | |
| EP2262911A4 (en) | COMPOSITIONS, PROCESSES AND KITS WITH SYNTHETIC PROBES FOR DETECTING THE PRESENCE OF A TARGET NUCLEIC ACID | |
| WO2011100541A3 (en) | Compositions and methods for the detection of small rnas | |
| GB201200658D0 (en) | Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence | |
| WO2012074904A3 (en) | Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents | |
| WO2012096545A3 (ko) | 췌장암 암줄기세포 특성을 이용한 췌장암 신규 바이오마커 및 그의 용도 | |
| EA201390149A1 (ru) | Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток | |
| WO2009086215A3 (en) | Pathway analysis of cell culture phenotypes and uses thereof | |
| ATE554389T1 (de) | Apex als marker für lungenkrebs | |
| EA201370063A1 (ru) | Фосфолипидом рака | |
| CA2839777C (en) | Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease | |
| WO2009055823A3 (en) | Method to predict responsiveness of breast cancer to polyaminetype chemotherapy | |
| WO2008085615A3 (en) | Methods for detection of a target nucleic acid by forming a cleavage structure with a cleavage resistant probe | |
| PH12016502411A1 (en) | Method for methylation analysis | |
| NO20093384L (no) | Sykdomsmarkorer | |
| WO2013106844A3 (en) | Methods and compositions for the treatment and diaginosis of pancreatic cancer | |
| EP2075341A4 (en) | METHOD FOR THE INVESTIGATION, DETERMINATION OR EVALUATION BY MEANS OF GENE EXPRESSION ANALYSIS | |
| NZ608316A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| WO2008054514A3 (en) | Differential expression profiling analysis of cell culture phenotypes and the uses thereof | |
| MX2020002787A (es) | Metodo para el analisis de metilacion. | |
| WO2008157299A3 (en) | Differential expression profiling analysis of cell culture phenotypes and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |